H

Hyundai BioLand Co Ltd
KOSDAQ:052260

Watchlist Manager
Hyundai BioLand Co Ltd
KOSDAQ:052260
Watchlist
Price: 4 310 KRW 0.23%
Market Cap: ₩129.3B

Net Margin

-2.5%
Current
Declining
by 6.2%
vs 3-y average of 3.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2.5%
=
Net Income
₩-3.1B
/
Revenue
₩125.3B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2.5%
=
Net Income
₩-3.1B
/
Revenue
₩125.3B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Hyundai BioLand Co Ltd
KOSDAQ:052260
129.3B KRW
Loading...
FR
L'Oreal SA
PAR:OR
202.5B EUR
Loading...
UK
Unilever PLC
LSE:ULVR
119.7B GBP
Loading...
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
5.6T INR
Loading...
UK
HALEON PLC
LSE:HLN
34.1B GBP
Loading...
US
Estee Lauder Companies Inc
NYSE:EL
42.1B USD
Loading...
DE
Beiersdorf AG
XETRA:BEI
21.2B EUR
Loading...
JP
Kao Corp
TSE:4452
2.8T JPY
Loading...
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
1.2T INR
Loading...
IN
Dabur India Ltd
NSE:DABUR
910.6B INR
Loading...
CA
Relevium Technologies Inc
XTSX:RLV
12.2B CAD
Loading...

Market Distribution

In line with most companies in Korea
Percentile
31th
Based on 2 632 companies
31th percentile
-2.5%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Hyundai BioLand Co Ltd
Glance View

Market Cap
129.3B KRW
Industry
Consumer products

HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2001-05-17. The firm operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.

Intrinsic Value
11 624.33 KRW
Undervaluation 63%
Intrinsic Value
Price
H
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-2.5%
=
Net Income
₩-3.1B
/
Revenue
₩125.3B
What is Hyundai BioLand Co Ltd's current Net Margin?

The current Net Margin for Hyundai BioLand Co Ltd is -2.5%, which is below its 3-year median of 3.6%.

How has Net Margin changed over time?

Over the last 3 years, Hyundai BioLand Co Ltd’s Net Margin has increased from -9.1% to -2.5%. During this period, it reached a low of -9.1% on Aug 30, 2022 and a high of 8.3% on Dec 31, 2023.

Back to Top